RxDoctor Payments Data

Albert Crook

Psychiatry · Coeur D'alene, IDNPI 1811985146

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,763 of the $5,345 with a category attached, or 89.1%. It is spread thinly across 16 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,345in general payments, 2019–2025

Across 224 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$679
  • Neurocrine Biosciences, Inc.$636
  • AbbVie$497
  • Lundbeck LLC$457
  • Sunovion Pharmaceuticals Inc.$424
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$4,76389%
  • Education$58311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,345 in reported general payments places this provider in the 90th percentile of 98 psychiatry providers in Idaho.

See all psychiatry providers in Idaho

Most prescribed under Part D

DrugClaimsCost to plans & patients
FetzimaLevomilnacipran Hcl12$4,966
Asenapine Maleate31$4,062
Aripiprazole11$3,228
Vilazodone Hcl15$1,338
Memantine Hcl47$1,238
Lurasidone Hcl28$1,112
Clozapine34$823
Duloxetine Hcl44$744
Lamotrigine113$598
Lithium Carbonate ErLithium Carbonate29$455
Gabapentin33$402
Bupropion XlBupropion Hcl28$379
Venlafaxine Hcl ErVenlafaxine Hcl21$334
Fluoxetine Hcl35$331
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieFetzima$497$4,96612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 98 psychiatry providers in Idaho.

Other psychiatry in Coeur D'alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →